MONOCLONAL ANTIBODY THERAPY FOR OBESITY
Genetics and Molecular Research · 07.07.2026
DOI: 10.4238/9gjkj977 ↗Kurz gefasst
Fachartikel in der Zeitschrift Genetics and Molecular Research, online erschienen am 07.07.2026. Verfasst von Alexander V. Blagov und 6 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-SA 4.0).
Abstract (Originalsprache)
Obesity is a complex, multifactorial disease in which the accumulation of excess body fat leads to negative health consequences. Its prevalence continues to accelerate, leading to an unprecedented epidemic that shows no significant signs of slowing anytime soon. An elevated body mass index (BMI) is a risk factor for noncommunicable diseases such as diabetes, cardiovascular disease, and musculoskeletal disorders, leading to a dramatic reduction in quality of life and life expectancy. Since most obese patients find it difficult to achieve and maintain successful long-term weight loss through lifestyle modifications (e.g., diet, exercise, and behavioral therapy), pharmacological approaches to obesity treatment should be considered as adjunctive therapies. Several monoclonal antibodies have been developed that are promising agents for the treatment of obesity.
Zitieren
APA
Blagov, A. V., Borodko, D. D., Melnikov, I., Rozhkova, U., Antonov, S., Utkina, A., & Orekhov, A. N. (2026). MONOCLONAL ANTIBODY THERAPY FOR OBESITY. Genetics and Molecular Research. https://doi.org/10.4238/9gjkj977
Vancouver
Blagov AV, Borodko DD, Melnikov I, Rozhkova U, Antonov S, Utkina A, et al. MONOCLONAL ANTIBODY THERAPY FOR OBESITY. Genetics and Molecular Research. 2026. doi:10.4238/9gjkj977
BibTeX
@article{Blagov2026,
author = {Blagov, Alexander V. and Borodko, Daria D. and Melnikov, Ivan and Rozhkova, Ulyana and Antonov, Stanislav and Utkina, Aleksandra and Orekhov, Alexander N.},
title = {MONOCLONAL ANTIBODY THERAPY FOR OBESITY},
journal = {Genetics and Molecular Research},
year = {2026},
doi = {10.4238/9gjkj977}
}
EUVIMED